title: Study the effects of PLGA-PEG encapsulated amphotericin B nanoparticle drug delivery system against Leishmania donovani.
abstract: Drug delivery systems are a promising technology to increase poor solubility and bioavailability of compounds. Therefore we have developed PLGA-PEG encapsulated amphotericin B nanoparticles (NPs) drug delivery technology to increase the solubility of amphotericin B and target the macrophage of infected tissues during visceral leishmaniasis. The structural characterization by transmission electron microscopy and dynamic light scattering revealed the nano-size of the particle (30-35 nanometers). Fourier transform infrared spectroscopy confirmed the PLGA-PEG encapsulation. The mean cytotoxic assay (0.0803 + 0.0253) of extracellular promastigote of PLGA-PEG encapsulated amphotericin B is significantly lower than that of amphotericin B (0.1134 + 0.0153) and inhibition of amastigotes in the splenic tissue was significantly more than with conventional amphotericin B (93.02 + 6.63 versus 74.42 +14.78). Amphotericin B encapsulated PLGA-PEG nanoparticles were found to be more effective than free amphotericin B in terms of therapeutic efficacy during in vitro and in vivo study.
authors.affiliation: Nanotechnology and Drug Discovery .
authors.forename: Rishikesh
authors.initials: R
authors.lastname: Kumar
authors.forename: Ganesh Chandra
authors.initials: GC
authors.lastname: Sahoo
authors.forename: Krishna
authors.initials: K
authors.lastname: Pandey
authors.forename: Vnr
authors.initials: V
authors.lastname: Das
authors.forename: Pradeep
authors.initials: P
authors.lastname: Das
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use; D006224:Cricetinae; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding; D005260:Female; D007893:Leishmania donovani / Q000187:drug effects*; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000469:parasitology; D046529:Microscopy, Electron, Transmission; D053758:Nanoparticles / Q000737:chemistry*; D021261:Parasitic Sensitivity Tests; D010316:Particle Size; D011092:Polyethylene Glycols / Q000737:chemistry*; D011098:Polyglactin 910 / Q000737:chemistry*; D013154:Spleen / Q000187:drug effects / Q000469:parasitology; D013499:Surface Properties
chemical_list: D000981:Antiprotozoal Agents; D004337:Drug Carriers; C102418:poly(lactic-glycolic acid)-poly(ethyleneglycol) copolymer; D011098:Polyglactin 910; D011092:Polyethylene Glycols; D000666:Amphotericin B
keywords: Amastigotes; PLGA-PEG; amphotericin B; electron microscope; kala azar; nanometer; promastigote